4.5 Review Book Chapter

Immunotoxin treatment of cancer

Journal

ANNUAL REVIEW OF MEDICINE
Volume 58, Issue -, Pages 221-237

Publisher

ANNUAL REVIEWS
DOI: 10.1146/annurev.med.58.070605.115320

Keywords

Pseudomonas toxin; diphtheria toxin; monoclonal antibody; recombinant immunotoxin

Funding

  1. NATIONAL CANCER INSTITUTE [Z01BC010301, ZIABC008753, ZIABC010301, Z01BC008753, ZIABC010816, Z01BC010816] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Immunotoxms are proteins used to treat cancer that are composed of an antibody fragment linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell by endocytosis, and kills it. The most potent immunotoxins are made from bacterial and plant toxins. Refinements over many years have produced recombinant immunotoxins; these therapeutic proteins are made using protein engineering. Individual immunotoxins are designed to treat specific cancers. To date, most success has been achieved treating hematologic tumors. Obstacles to successful treatment of solid tumors include poor penetration into tumor masses and the immune response to the toxin component of the immunotoxin, which limits the number of cycles that can be given. Strategies to overcome these limitations are being pursued.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available